Unknown

Dataset Information

0

IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.


ABSTRACT: PURPOSE:To improve persistence of adoptively transferred T-cell receptor (TCR)-engineered T cells and durable clinical responses, we designed a clinical trial to transplant genetically-modified hematopoietic stem cells (HSCs) together with adoptive cell transfer of T cells both engineered to express an NY-ESO-1 TCR. Here, we report the preclinical studies performed to enable an investigational new drug (IND) application. EXPERIMENTAL DESIGN:HSCs transduced with a lentiviral vector expressing NY-ESO-1 TCR and the PET reporter/suicide gene HSV1-sr39TK and T cells transduced with a retroviral vector expressing NY-ESO-1 TCR were coadministered to myelodepleted HLA-A2/Kb mice within a formal Good Laboratory Practice (GLP)-compliant study to demonstrate safety, persistence, and HSC differentiation into all blood lineages. Non-GLP experiments included assessment of transgene immunogenicity and in vitro viral insertion safety studies. Furthermore, Good Manufacturing Practice (GMP)-compliant cell production qualification runs were performed to establish the manufacturing protocols for clinical use. RESULTS:TCR genetically modified and ex vivo-cultured HSCs differentiated into all blood subsets in vivo after HSC transplantation, and coadministration of TCR-transduced T cells did not result in increased toxicity. The expression of NY-ESO-1 TCR and sr39TK transgenes did not have a detrimental effect on gene-modified HSC's differentiation to all blood cell lineages. There was no evidence of genotoxicity induced by the lentiviral vector. GMP batches of clinical-grade transgenic cells produced during qualification runs had adequate stability and functionality. CONCLUSIONS:Coadministration of HSCs and T cells expressing an NY-ESO-1 TCR is safe in preclinical models. The results presented in this article led to the FDA approval of IND 17471.

SUBMITTER: Puig-Saus C 

PROVIDER: S-EPMC6359988 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.

Puig-Saus Cristina C   Parisi Giulia G   Garcia-Diaz Angel A   Krystofinski Paige E PE   Sandoval Salemiz S   Zhang Ruixue R   Champhekar Ameya S AS   McCabe James J   Cheung-Lau Gardenia C GC   Truong Nhat A NA   Vega-Crespo Agustin A   Komenan Marie Desiles S MDS   Pang Jia J   Macabali Mignonette H MH   Saco Justin D JD   Goodwin Jeffrey L JL   Bolon Brad B   Seet Christopher S CS   Montel-Hagen Amelie A   Crooks Gay M GM   Hollis Roger P RP   Campo-Fernandez Beatriz B   Bischof Daniela D   Cornetta Kenneth K   Gschweng Eric H EH   Adelson Celia C   Nguyen Alexander A   Yang Lili L   Witte Owen N ON   Baltimore David D   Comin-Anduix Begonya B   Kohn Donald B DB   Wang Xiaoyan X   Cabrera Paula P   Kaplan-Lefko Paula J PJ   Berent-Maoz Beata B   Ribas Antoni A  

Clinical cancer research : an official journal of the American Association for Cancer Research 20181108 3


<h4>Purpose</h4>To improve persistence of adoptively transferred T-cell receptor (TCR)-engineered T cells and durable clinical responses, we designed a clinical trial to transplant genetically-modified hematopoietic stem cells (HSCs) together with adoptive cell transfer of T cells both engineered to express an NY-ESO-1 TCR. Here, we report the preclinical studies performed to enable an investigational new drug (IND) application.<h4>Experimental design</h4>HSCs transduced with a lentiviral vector  ...[more]

Similar Datasets

| S-EPMC9320065 | biostudies-literature
| S-EPMC8748802 | biostudies-literature
| S-EPMC4846560 | biostudies-literature
| S-EPMC6234660 | biostudies-literature
2024-08-21 | GSE275158 | GEO
| S-EPMC6698958 | biostudies-literature
2024-08-21 | GSE275157 | GEO
2024-08-21 | GSE275063 | GEO
2024-09-14 | GSE277175 | GEO
2024-09-14 | GSE277176 | GEO